search
Back to results

Prospective Study Assessing Thyroidectomy Using Robot (EVATAR)

Primary Purpose

Patients With Thyroid Cancer

Status
Unknown status
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Da Vinci Xi
Sponsored by
Gustave Roussy, Cancer Campus, Grand Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patients With Thyroid Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Benign thyroid nodule or follicular or suspicious cytological (Bethesda classifications 2, 3, 4, or 5) requiring thyroid lobectomy or total thyroidectomy therapeutic or diagnostic
  2. Differentiated thyroid cancers - CN0 (no suspicious lymph node in the central or lateral compartments on preoperative ultrasound - CN1A / b with lymph node metastases <or = 10 mm in areas VI, III and / or IV, detected on preoperative ultrasound - For which the indication of a lobectomy or total thyroidectomy, with or without dissection of the central compartment and / or lateral neck was put in multidisciplinary meeting
  3. Patient with no cons-indication to thyroid surgery or without dissection
  4. Patient general condition of WHO grade 0-1
  5. Patient age > 18 years and able to comply with the protocol visits
  6. Patient agreeing to undergo robot-assisted surgery, the incision being at patient choice, depending on the wishes concerning the location of the scar (Axillary or behind the ear channel)
  7. Patient Information or his legal representative and signed consent enlightened
  8. Patient affiliated to a system of social security or beneficiary of such a scheme

Exclusion Criteria:

  1. A history of cervical surgery or external beam radiation therapy
  2. Anomaly craniocervical hinge or symptomatic cervical spondylosis
  3. Congenital or acquired shoulder or ipsilateral upper limb surgery (for axillary )
  4. paralysis preoperatively ( a laryngoscopic examination will be performed systematically preoperatively )
  5. tumors with obvious extra- thyroid extension or suspected during preoperative ( cT3T4 )
  6. metastatic cervical lymphadenopathy > 10 mm during the preoperative
  7. Pregnant women or during lactation
  8. patient already included in another clinical trial with a molecule experimental

Sites / Locations

  • Gustave Roussy

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Da Vinci Xi

Arm Description

Outcomes

Primary Outcome Measures

Efficacy for benign tumor
If total thyroidectomy : rate of patients with thyroglobulin (Tg) under non- suppressive treatment with L-thyroxine ( LT4 ) <2 ng / ml to 3 months with a target value TSH between 0.5 and 2 ng / mL If lobectomy : size of the remaining thyroid ipsilateral to the surgery evaluated sonographically <11 mm ( larger diameter ) to 3 months
Efficacy for malignant tumor
Rate of patients in complete remission at 12 months, remission defined as no biological or radiological anomaly: Tg / LT4 < 2 ng / ml in the absence of treatment with 131I ( in the absence of anti Tg antibodies) or Tg / LT4 <0.2 ng / mL in patients treated with 131I (absent anti Tg antibody ) Normal cervical ultrasound Normal SPECT -CT if treatment with 131I If realized : CT and / or normal 18 FDG - PET

Secondary Outcome Measures

Full Information

First Posted
July 12, 2016
Last Updated
June 13, 2018
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT02839655
Brief Title
Prospective Study Assessing Thyroidectomy Using Robot
Acronym
EVATAR
Official Title
Prospective Study Assessing Thyroidectomy Using Robot
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
June 30, 2016 (Actual)
Primary Completion Date
May 15, 2018 (Actual)
Study Completion Date
August 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gustave Roussy, Cancer Campus, Grand Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The robot-assisted surgery for benign and malignant thyroid tumors was widely developed in Asia and begins to spread in Western countries. The main advantage of the technique is to avoid a scar in the neck by placing it either in the axilla or at the hairline behind the ear to improve esthetic consequences and body image. It is not surgery minimally invasive but rather a way of remote access surgery. Data from the literature including cohort studies and meta-analyzes attest the security of the procedure in comparison with classic thyroid surgery (which remains the "gold standard"). However there is few data on the effectiveness of the technique in terms of the completeness of the surgery, according to the routine standard criteria used in endocrinology and endocrine cancer, and no French medico-economic study has been performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patients With Thyroid Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Da Vinci Xi
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Da Vinci Xi
Primary Outcome Measure Information:
Title
Efficacy for benign tumor
Description
If total thyroidectomy : rate of patients with thyroglobulin (Tg) under non- suppressive treatment with L-thyroxine ( LT4 ) <2 ng / ml to 3 months with a target value TSH between 0.5 and 2 ng / mL If lobectomy : size of the remaining thyroid ipsilateral to the surgery evaluated sonographically <11 mm ( larger diameter ) to 3 months
Time Frame
Assessed 3 months after surgery
Title
Efficacy for malignant tumor
Description
Rate of patients in complete remission at 12 months, remission defined as no biological or radiological anomaly: Tg / LT4 < 2 ng / ml in the absence of treatment with 131I ( in the absence of anti Tg antibodies) or Tg / LT4 <0.2 ng / mL in patients treated with 131I (absent anti Tg antibody ) Normal cervical ultrasound Normal SPECT -CT if treatment with 131I If realized : CT and / or normal 18 FDG - PET
Time Frame
Assessed 12 months after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Benign thyroid nodule or follicular or suspicious cytological (Bethesda classifications 2, 3, 4, or 5) requiring thyroid lobectomy or total thyroidectomy therapeutic or diagnostic Differentiated thyroid cancers - CN0 (no suspicious lymph node in the central or lateral compartments on preoperative ultrasound - CN1A / b with lymph node metastases <or = 10 mm in areas VI, III and / or IV, detected on preoperative ultrasound - For which the indication of a lobectomy or total thyroidectomy, with or without dissection of the central compartment and / or lateral neck was put in multidisciplinary meeting Patient with no cons-indication to thyroid surgery or without dissection Patient general condition of WHO grade 0-1 Patient age > 18 years and able to comply with the protocol visits Patient agreeing to undergo robot-assisted surgery, the incision being at patient choice, depending on the wishes concerning the location of the scar (Axillary or behind the ear channel) Patient Information or his legal representative and signed consent enlightened Patient affiliated to a system of social security or beneficiary of such a scheme Exclusion Criteria: A history of cervical surgery or external beam radiation therapy Anomaly craniocervical hinge or symptomatic cervical spondylosis Congenital or acquired shoulder or ipsilateral upper limb surgery (for axillary ) paralysis preoperatively ( a laryngoscopic examination will be performed systematically preoperatively ) tumors with obvious extra- thyroid extension or suspected during preoperative ( cT3T4 ) metastatic cervical lymphadenopathy > 10 mm during the preoperative Pregnant women or during lactation patient already included in another clinical trial with a molecule experimental
Facility Information:
Facility Name
Gustave Roussy
City
Villejuif
State/Province
Val De Marne
ZIP/Postal Code
94805
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prospective Study Assessing Thyroidectomy Using Robot

We'll reach out to this number within 24 hrs